The Semaglutide and Cardiovascular Outcomes (SELECT) trial, which involved approximately 17,600 overweight or obese adults with pre-existing cardiovascular disease, has provided groundbreaking data on the benefits of semaglutide on heart health. Funded by Novo Nordisk, the trial revealed that weekly injections of semaglutide over a period of three years could reduce the risk of stroke, heart attack, or fatal cardiovascular events by almost 20 percent, on average.
Recent findings by cardiologist John Deanfield and his team from University College London have shown that the cardiovascular benefits of semaglutide occur irrespective of weight loss. Participants in the SELECT trial experienced a decrease in the risk of adverse cardiovascular events, such as heart attacks or strokes, regardless of their starting weight or the weight they lost while on semaglutide treatment.
Semaglutide, originally developed to treat diabetes, has gained popularity for its ability to suppress appetite and induce rapid weight loss. While previous clinical trials have demonstrated the cardiovascular benefits of semaglutide in individuals with diabetes, its effects on patients without insulin issues have been less clear. However, a recent analysis of the SELECT trial revealed sustained weight loss, averaging 10 percent over four years, across a diverse population. This weight loss could potentially impact the burden of various obesity-related illnesses beyond cardiovascular disease.
Although semaglutide is known for its efficacy in treating obesity, researchers suggest that not all of its health benefits stem from weight loss alone. There may be other mechanisms at play that go beyond the reduction in body fat. The unexpected effects of semaglutide on heart health have the potential to change the way scientists perceive the relationship between obesity and cardiovascular disease.
While the findings from the SELECT trial and subsequent analyses are promising, further research is needed to fully understand the long-term impacts of semaglutide on weight loss and cardiovascular risks. Concerns have been raised about potential weight regain once semaglutide treatment is discontinued, as well as the need for a more comprehensive understanding of how the drug functions. Until more is known about semaglutide’s mechanisms of action, caution is advised in widespread use of the medication.
The medicine behind Ozempic and Wegovy, semaglutide, has shown significant potential in improving heart health, regardless of weight loss. The findings from the SELECT trial and subsequent research underscore the importance of continued investigation into the effects of semaglutide on cardiovascular outcomes and overall health. As scientists delve deeper into the mechanisms of semaglutide, new insights may emerge that could revolutionize the treatment of obesity and cardiovascular disease.
Leave a Reply